ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
University of Pittsburgh
Study ID
NCT07332975
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This translational biomarker study will collect blood in patients Stage I triple negative breast cancer at diagnosis prior to either neoadjuvant treatment or surgery and then during treatment.

Key Dates

Start date
Jan 20, 2026
Status verified
Mar 2026
Primary completion
Jan 20, 2029
Completion
Jan 20, 2029

Study Design

Enrollment
77 participants (estimated)

Primary Outcome Measure

ctDNA detection [ Time Frame: Up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Hillman CancerPittsburghPennsylvania15232
Kelsey Mitch, BSN
[email protected]
4126412357
Lucia M Borrasso, BSN
[email protected]
412-641-3304
Marija Balic, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
UPMC Hillman Cancer· Pittsburgh, PA

Related Studies